Yes this study is getting fantastic coverage and the test wouldn't be available for general use until 2015 at the earliest. Whoever is in charge of this PR surely knows how to play the media. When Arrayit announced that it was going to submit application to the FDA etc it did not get this kind of coverage in the main stream media (MSM) only the bio and medical media. As you say Arrayit has to put something out to INTRODUCE Ovadx to the MSM and compare and contrat OvaDx to this study.
Market Data 
Markets 
AI
